TCT-18 Real-World Comparative Outcomes of Tirzepatide and Dulaglutide in Adults With Type 2 Diabetes Mellitus: A TriNetX Propensity Score–Matched Cohort Study
JACC · 2026-11 · 88 (18) · B7-B8
DOI: 10.1016/j.jacc.2026.09.059 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift JACC, 2026-11. Verfasst von Taha Alam und 12 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Alam, T., Kholeif, Z., Kamal, S., Hussain, M., Mustafa, M. S., Zaman, A., basit, A., Hassan, M., Nisa, N. U., Kachhadia, M. P., Usman, M. T., Khan, H., & Ahamed, M. S. I. (2026). TCT-18 Real-World Comparative Outcomes of Tirzepatide and Dulaglutide in Adults With Type 2 Diabetes Mellitus: A TriNetX Propensity Score–Matched Cohort Study. JACC, 88(18), B7-B8. https://doi.org/10.1016/j.jacc.2026.09.059
Vancouver
Alam T, Kholeif Z, Kamal S, Hussain M, Mustafa MS, Zaman A, et al. TCT-18 Real-World Comparative Outcomes of Tirzepatide and Dulaglutide in Adults With Type 2 Diabetes Mellitus: A TriNetX Propensity Score–Matched Cohort Study. JACC. 2026;88(18):B7-B8. doi:10.1016/j.jacc.2026.09.059
BibTeX
@article{Alam2026,
author = {Alam, Taha and Kholeif, Zeyad and Kamal, Sohaima and Hussain, Muhammad and Mustafa, Muhammad Salman and Zaman, Asad and basit, Abdul and Hassan, Muhammad and Nisa, Noor Un and Kachhadia, Meet Popatbhai and Usman, Muhammad Talha and Khan, Hammad and Ahamed, Mohamed Shabbeer Imtiaz},
title = {TCT-18 Real-World Comparative Outcomes of Tirzepatide and Dulaglutide in Adults With Type 2 Diabetes Mellitus: A TriNetX Propensity Score–Matched Cohort Study},
journal = {JACC},
year = {2026},
volume = {88},
number = {18},
pages = {B7--B8},
doi = {10.1016/j.jacc.2026.09.059}
}
EUVIMED